{"id":56910,"date":"2026-02-11T22:27:37","date_gmt":"2026-02-11T14:27:37","guid":{"rendered":"https:\/\/flcube.com\/?p=56910"},"modified":"2026-02-11T22:27:38","modified_gmt":"2026-02-11T14:27:38","slug":"cascade-pharma-raises-72-million-to-advance-mash-and-obesity-pipeline-to-phase-iii","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56910","title":{"rendered":"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III"},"content":{"rendered":"\n<p><strong>Cascade Pharmaceuticals, Inc.<\/strong>, a <strong>Shanghai-based sino-foreign joint venture<\/strong>, has <strong>closed a RMB\u202f500 million (USD\u202f72.34 million) financing round<\/strong> led by <strong>ESG Investment<\/strong>, with participation from <strong>China Life Capital, Tsing Song Capital, Qingdao Conson Financial Holdings<\/strong>, and returning investors <strong>GaoRong Ventures and Bayland Capital<\/strong>. The proceeds will <strong>accelerate global Phase III trials<\/strong> for its <strong>nuclear receptor and GPCR-targeted metabolic disease portfolio<\/strong>, including <strong>MASH, PBC, PSC, and obesity indications<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-overview\">Financing Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Cascade Pharmaceuticals, Inc. (Shanghai-based JV)<\/td><\/tr><tr><td><strong>Amount Raised<\/strong><\/td><td><strong>RMB\u202f500 million (USD\u202f72.34 million)<\/strong><\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>ESG Investment<\/td><\/tr><tr><td><strong>New Investors<\/strong><\/td><td>China Life Capital, Tsing Song Capital, Qingdao Conson Financial Holdings<\/td><\/tr><tr><td><strong>Returning Investors<\/strong><\/td><td>GaoRong Ventures, Bayland Capital<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2017<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Nuclear receptors and GPCRs for metabolic diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-amp-clinical-strategy\">Pipeline &amp; Clinical Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Target Indications<\/th><th>Development Stage<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>MASH\/MASLD<\/strong><\/td><td>Metabolic dysfunction-associated steatohepatitis<\/td><td><strong>Global Phase III initiation<\/strong><\/td><td>$20B+ market; no approved therapies; first-mover advantage window<\/td><\/tr><tr><td><strong>PBC<\/strong><\/td><td>Primary biliary cholangitis<\/td><td>Phase III preparation<\/td><td>Orphan indication with high unmet need; ODD eligibility<\/td><\/tr><tr><td><strong>PSC<\/strong><\/td><td>Primary sclerosing cholangitis<\/td><td>Pipeline expansion<\/td><td>Rare cholestatic disease; limited treatment options<\/td><\/tr><tr><td><strong>Obesity<\/strong><\/td><td>Metabolic disease complications<\/td><td>Early development<\/td><td>Adjunct to GLP-1 therapy; nuclear receptor mechanism differentiation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism Focus:<\/strong> <strong>Nuclear receptors (FXR, PPARs)<\/strong> and <strong>GPCRs<\/strong> \u2013 validated targets for <strong>metabolic regulation, bile acid homeostasis, and inflammation resolution<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-use-of-proceeds-amp-strategic-priorities\">Use of Proceeds &amp; Strategic Priorities<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Priority<\/th><th>Allocation<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Phase III Execution<\/strong><\/td><td>Lead asset MASH\/PBC registration trials<\/td><td>2026-2028<\/td><\/tr><tr><td><strong>Global Registration<\/strong><\/td><td>NDA submissions in US, EU, China<\/td><td>2028-2029<\/td><\/tr><tr><td><strong>Pipeline Expansion<\/strong><\/td><td>Next-generation nuclear receptor\/GPCR modulators<\/td><td>Ongoing<\/td><\/tr><tr><td><strong>Best-in-Class\/First-in-Class R&amp;D<\/strong><\/td><td>Novel target validation and lead optimization<\/td><td>2026-2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-positioning\">Market Context &amp; Competitive Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>MASH Market Opportunity<\/strong><\/td><td><strong>NASH\/MASH affects &gt;100 million patients globally<\/strong>; <strong>resmetirom (Madrigal)<\/strong> first approved 2024; <strong>significant room for mechanism differentiation<\/strong><\/td><\/tr><tr><td><strong>Nuclear Receptor Validation<\/strong><\/td><td><strong>FXR agonists<\/strong> (obeticholic acid, tropifexor) and <strong>PPAR modulators<\/strong> (elafibranor, lanifibranor) demonstrate efficacy; <strong>next-generation selectivity<\/strong> key to safety improvement<\/td><\/tr><tr><td><strong>China Biotech Funding Environment<\/strong><\/td><td><strong>RMB\u202f500 million Series C+<\/strong> represents <strong>significant vote of confidence<\/strong> in metabolic disease focus; <strong>ESG Investment lead<\/strong> signals institutional quality<\/td><\/tr><tr><td><strong>Sino-Foreign JV Structure<\/strong><\/td><td>Enables <strong>global regulatory strategy<\/strong> (US FDA, EMA) while maintaining <strong>China development and manufacturing advantages<\/strong><\/td><\/tr><tr><td><strong>GPCR Differentiation<\/strong><\/td><td><strong>Orally bioavailable small molecules<\/strong> vs. injectable biologics; <strong>combination potential with GLP-1 agonists<\/strong> for comprehensive metabolic management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Cascade Pharma Phase III trial execution, MASH regulatory approval timelines, and metabolic disease pipeline expansion. Actual results may differ due to competitive dynamics with Madrigal, Intercept, and 89bio, nuclear receptor safety profile challenges, and global clinical trial enrollment variability.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB\u202f500 million (USD\u202f72.34 million)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2399],"class_list":["post-56910","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cascade-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB\u202f500 million (USD\u202f72.34 million) financing round led by ESG Investment, with participation from China Life Capital, Tsing Song Capital, Qingdao Conson Financial Holdings, and returning investors GaoRong Ventures and Bayland Capital. The proceeds will accelerate global Phase III trials for its nuclear receptor and GPCR-targeted metabolic disease portfolio, including MASH, PBC, PSC, and obesity indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56910\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III\" \/>\n<meta property=\"og:description\" content=\"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB\u202f500 million (USD\u202f72.34 million) financing round led by ESG Investment, with participation from China Life Capital, Tsing Song Capital, Qingdao Conson Financial Holdings, and returning investors GaoRong Ventures and Bayland Capital. The proceeds will accelerate global Phase III trials for its nuclear receptor and GPCR-targeted metabolic disease portfolio, including MASH, PBC, PSC, and obesity indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56910\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T14:27:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T14:27:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56910#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56910\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III\",\"datePublished\":\"2026-02-11T14:27:37+00:00\",\"dateModified\":\"2026-02-11T14:27:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56910\"},\"wordCount\":423,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cascade Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56910#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56910\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56910\",\"name\":\"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-11T14:27:37+00:00\",\"dateModified\":\"2026-02-11T14:27:38+00:00\",\"description\":\"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB\u202f500 million (USD\u202f72.34 million) financing round led by ESG Investment, with participation from China Life Capital, Tsing Song Capital, Qingdao Conson Financial Holdings, and returning investors GaoRong Ventures and Bayland Capital. The proceeds will accelerate global Phase III trials for its nuclear receptor and GPCR-targeted metabolic disease portfolio, including MASH, PBC, PSC, and obesity indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56910#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56910\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56910#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III - Insight, China&#039;s Pharmaceutical Industry","description":"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB\u202f500 million (USD\u202f72.34 million) financing round led by ESG Investment, with participation from China Life Capital, Tsing Song Capital, Qingdao Conson Financial Holdings, and returning investors GaoRong Ventures and Bayland Capital. The proceeds will accelerate global Phase III trials for its nuclear receptor and GPCR-targeted metabolic disease portfolio, including MASH, PBC, PSC, and obesity indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56910","og_locale":"en_US","og_type":"article","og_title":"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III","og_description":"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB\u202f500 million (USD\u202f72.34 million) financing round led by ESG Investment, with participation from China Life Capital, Tsing Song Capital, Qingdao Conson Financial Holdings, and returning investors GaoRong Ventures and Bayland Capital. The proceeds will accelerate global Phase III trials for its nuclear receptor and GPCR-targeted metabolic disease portfolio, including MASH, PBC, PSC, and obesity indications.","og_url":"https:\/\/flcube.com\/?p=56910","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T14:27:37+00:00","article_modified_time":"2026-02-11T14:27:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56910#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56910"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III","datePublished":"2026-02-11T14:27:37+00:00","dateModified":"2026-02-11T14:27:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56910"},"wordCount":423,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cascade Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56910#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56910","url":"https:\/\/flcube.com\/?p=56910","name":"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-11T14:27:37+00:00","dateModified":"2026-02-11T14:27:38+00:00","description":"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB\u202f500 million (USD\u202f72.34 million) financing round led by ESG Investment, with participation from China Life Capital, Tsing Song Capital, Qingdao Conson Financial Holdings, and returning investors GaoRong Ventures and Bayland Capital. The proceeds will accelerate global Phase III trials for its nuclear receptor and GPCR-targeted metabolic disease portfolio, including MASH, PBC, PSC, and obesity indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56910#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56910"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56910#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56910"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56910\/revisions"}],"predecessor-version":[{"id":56911,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56910\/revisions\/56911"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}